FDA 483 OBSERVATION · #64 OF 1,945 MOST-CITED
Training - Lack of or inadequate procedures
FDA cited this observation 385 times across 362 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
21 CFR 820.25 (Personnel) is a Quality System Regulation section; since QMSR took effect on 2 February 2026 FDA inspects this as “Human Resources”: ISO 13485 clause 6.2 (CP 7382.850 Attachment A).
The device manufacturer lacked adequate procedures to identify training needs and ensure personnel were trained to perform their assigned responsibilities, so staff may have performed GxP tasks without demonstrated competence.
Why FDA writes it — People execute every quality control the system defines. Untrained personnel — especially where errors have quality or safety consequences — is a direct route to defects, so FDA cites inadequate training as a first-order systemic weakness.
- Establish procedures for identifying training needs and ensuring all personnel are trained to adequately perform their assigned responsibilities.
- Make personnel aware of device defects that may occur from improper performance of their jobs, and of the consequences of their errors.
- Train those performing verification and validation activities in the defects and errors they may encounter.
- Document training and keep records current.
- Training recorded as one-time onboarding and never refreshed as roles or procedures change.
- No linkage between the task’s quality risk and the training required for it.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.8× the rate of the average FDA-cited firm (14.4% vs 7.8%), across 362 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Procedures for training and identifying training needs have not been adequately established.
Procedures for training and identifying training needs have not been adequately established.
Procedures for training and identifying training needs have not been adequately established.
Procedures for training and identifying training needs have not been adequately established.
Procedures for training and identifying training needs have not been adequately established.
Procedures for training and identifying training needs have not been established.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →